PegFilgrastim
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1102 publications
Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial.
Journal: Annals of internal medicine
Published: March 23, 2026
Summary for Patients: Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain.
Journal: Annals of internal medicine
Published: March 23, 2026
Cancer-associated thrombosis presenting as multiple brain infarctions during complete remission of follicular lymphoma.
Journal: Internal medicine (Tokyo, Japan)
Published: March 11, 2026
Correction to: REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.
Journal: JNCI cancer spectrum
Published: March 11, 2026
Cytokine use in the Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS): Implications for the role of cytokines in a mass casualty radiologic/nuclear (R/N) emergency.
Journal: Journal of radiological protection : official journal of the Society for Radiological Protection
Published: February 12, 2026
Bone Marrow Colony Stimulating Factors (CSF) and Stem Cell Therapy as Medical Countermeasures (MCM) for Treatment of Hematopoietic-Acute Radiation Syndrome: A Systematic Review.
Journal: Disaster medicine and public health preparedness
Published: February 09, 2026
Efficacy of pegfilgrastim in preventing febrile neutropenia during DCF chemotherapy for esophageal cancer: A systematic review and meta-analysis.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: January 29, 2026
Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.
Journal: JAMA network open
Published: January 15, 2026
Correction to "Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development".
Journal: Clinical pharmacology and therapeutics
Published: December 02, 2025
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
Journal: JAMA network open
Published: November 11, 2025
From Aortitis to Sweet's: The Immune Spectrum of G-CSF Adverse Events.
Journal: Seminars in arthritis and rheumatism
Published: October 28, 2025
Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.
Journal: Japanese journal of clinical oncology
Published: October 24, 2025
Last Updated: 04/28/2026